As of 2025-10-28, the EV/EBITDA ratio of Fulcrum Therapeutics Inc (FULC) is -8.76. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FULC's latest enterprise value is 456.12 mil USD. FULC's TTM EBITDA according to its financial statements is -52.06 mil USD. Dividing these 2 quantities gives us the above FULC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.0x - 11.0x | 7.8x |
| Forward P/E multiples | 9.3x - 16.1x | 12.8x |
| Fair Price | (8.13) - (9.80) | (9.15) |
| Upside | -188.1% - -206.3% | -199.2% |
| Date | EV/EBITDA |
| 2025-10-17 | -8.52 |
| 2025-10-16 | -8.83 |
| 2025-10-15 | -9.20 |
| 2025-10-14 | -8.21 |
| 2025-10-13 | -8.27 |
| 2025-10-10 | -8.52 |
| 2025-10-09 | -9.18 |
| 2025-10-08 | -9.19 |
| 2025-10-07 | -8.78 |
| 2025-10-06 | -9.05 |
| 2025-10-03 | -8.76 |
| 2025-10-02 | -9.06 |
| 2025-10-01 | -8.88 |
| 2025-09-30 | -8.74 |
| 2025-09-29 | -8.19 |
| 2025-09-26 | -8.37 |
| 2025-09-25 | -8.01 |
| 2025-09-24 | -7.75 |
| 2025-09-23 | -6.82 |
| 2025-09-22 | -6.92 |
| 2025-09-19 | -6.86 |
| 2025-09-18 | -7.02 |
| 2025-09-17 | -6.79 |
| 2025-09-16 | -6.77 |
| 2025-09-15 | -6.53 |
| 2025-09-12 | -6.45 |
| 2025-09-11 | -6.44 |
| 2025-09-10 | -6.44 |
| 2025-09-09 | -6.70 |
| 2025-09-08 | -6.74 |
| 2025-09-05 | -7.14 |
| 2025-09-04 | -6.33 |
| 2025-09-03 | -5.96 |
| 2025-09-02 | -5.84 |
| 2025-08-29 | -5.91 |
| 2025-08-28 | -6.09 |
| 2025-08-27 | -6.07 |
| 2025-08-26 | -5.96 |
| 2025-08-25 | -5.84 |
| 2025-08-22 | -6.33 |
| 2025-08-21 | -5.96 |
| 2025-08-20 | -6.01 |
| 2025-08-19 | -6.05 |
| 2025-08-18 | -6.08 |
| 2025-08-15 | -6.27 |
| 2025-08-14 | -6.04 |
| 2025-08-13 | -6.30 |
| 2025-08-12 | -5.98 |
| 2025-08-11 | -5.77 |
| 2025-08-08 | -5.92 |